|
Johnson & Johnson (J&J) has announced a strategic agreement and collaboration with Sail Biomedicines, a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases.
As per the agreement, Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease programme and broader platform technology, with incentives to expand the application of Sail Biomedicines' in vivo CAR-T platform across additional therapeutic targets over time. Johnson & Johnson will also make an equity investment in Sail Biomedicines. Additionally, Johnson & Johnson has been granted an exclusive option to acquire Sail Biomedicines for $2.58 billion.
This advances in differentiated immunology programme with the potential to address significant unmet need in immune-mediated disease.
Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential.
In vivo CAR-T therapies represent one of the most promising frontiers in medicine, with the potential to deliver transformative therapies across a range of cancer and immune-mediated diseases. Unlike traditional cell therapies, Sail Biomedicines’ lead programme and platform are designed to reprogram a patient’s immune cells directly within the body, with the goal of resetting the immune system and delivering durable disease control. Through this collaboration, Johnson & Johnson and Sail Biomedicines will combine their expertise to advance innovative in vivo CAR-T therapies that have the potential to improve patient outcomes and ultimately deliver curative treatment approaches for people living with complex diseases.
“People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control,” said John Reed, executive vice president, innovative medicine research & development, Johnson & Johnson. “Sail Biomedicines’ innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way. By working together with Sail Biomedicines, we aim to accelerate the development of innovative therapies that have the potential to fundamentally transform how immune-mediated diseases are treated.”
Building on its leadership in immunology and established expertise in CAR-T therapy within oncology, Johnson & Johnson continues to invest in emerging technologies with the potential to reshape disease treatment and transform patient outcomes. The agreement with Sail Biomedicines expands the company’s capabilities in in vivo CAR-T, strengthens its position at the forefront of immune system reprogramming and immune reset, and creates opportunities to advance future programs across a range of complex diseases.
Under the terms of the agreements, Johnson & Johnson would make total initial payments of $785 million, including a $465 million equity investment, and additional contingent payments of $140 million if certain development milestones are achieved. Subject to Johnson & Johnson’s decision to exercise the option, Johnson & Johnson would make an additional payment of $2.58 billion. Assuming exercise of the option, Johnson & Johnson expects the agreements to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.18 in 2026 and approximately $1.28 in 2027.
The transactions are subject to applicable regulatory approvals and/or other conditions.
|